PHARMACOGENETIC PROFILE AND PERSONALIZATION POSSIBILITIESIN TREATMENT OF PATIENTS WITH CHRONIC PELVIC PAIN SYNDROME

R.M. Mamina Mamina, Б. И. Кантемирова, А В Жидовинов, Vladimir V. Belopasov, Ekaterina Orlova, Р. А. Садретдинов, Kristina Tatzhikova, М. А. Абдуллаев
In: Archiv Euromedica · 2021 · vol. 11(1) , pp. 56–59 · doi:10.35630/2199-885x/2021/11/1.11 · W3146987528
article OA: bronze CC0
🔓 Open OA copy View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-10 ⓘ

This study investigated the pharmacogenetic profile of the CYP2C9 gene in chronic pelvic pain syndrome patients to enable personalized NSAID therapy and mitigate side effects.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Chronic pelvic pain syndrome (CPPS) is equally common in both men and women, causes worsening quality of life, social isolation and disability. The treatment of CPPS requires long-term pharmacotherapy associated with the development of class-specific side effects of nonsteroidal anti-inflammatory drugs (NSAIDs). Genetic study of the carriage of polymorphic alleles of the CYP2C9 gene involved in the metabolism of non-steroidal anti-inflammatory drugs (NSAIDs) prescribed to patients with CPPS is an urgent and in-demand task of modern healthcare. This study allows us not only to determine the genotypes of patients with CPPS but also to identify ways of personalized approach to therapy

My notes (saved in your browser only)

Condition tags

chronic_pelvic_pain

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

References (6)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK